Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

effective at 5:00 p.m. EDT on Tuesday, August 20, 2013.

Stockholders holding shares in "street name" through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split and change in name.  

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.  The Company's product Ceplene®, when used concomitantly with low-dose IL-2 is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.  The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012.  The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.  In November 2012, EpiCept and Immune Pharmaceuticals Ltd., a privately held Israeli company, entered into a definitive merger agreement.  The transaction is anticipated to close this week.  The combined company will be focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.

About Immune Pharmaceuticals Ltd.

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics to address unmet medical needs in the treatment of inflammatory diseases and cancer. Im
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... on health care, Jack Uldrich has been selected ... in New York today. He will deliver his ... , Uldrich has delivered presentations to the American ... of Audiology and Neurology, Alcetel-Lucent/Verizon Forum on Wireless ...
(Date:6/1/2015)... and RARITAN, N.J. , June ... (Janssen) announced data from the Phase 3 multicenter ... progression-free survival (PFS) with trabectedin (YONDELIS ® ) ... (LPS) or leiomyosarcoma (LMS) previously treated with an ... SAR3007 is the largest randomized Phase 3 study ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3
... Nov. 24 Terumo Heart, Inc. is pleased to,announce ... Chief Executive,Officer (C.E.O.) and President, effective immediately. "With its ... leadership role in,the future treatment of heart failure. I ... DuraHeart U.S. Pivotal trials in up to 40 clinical ...
... LAKE, N.J., Nov. 24 Eisai Inc., in ... of the,C.A.R.E. (Commitment to Alzheimer,s. Recognition of Excellence.) ... pharmacist who has been,nominated by a person with ... her,exceptional impact on the lives of those fighting ...
... companies serving biotech/pharma industry to find new business opportunities and ... ... (PRWEB) November 24, 2008 -- In response to challenging economic ... its PharmSource Lead Sheet, a weekly web-based service that reports ...
Cached Biology Technology:Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President 2Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award 2Eisai Inc. and the Alzheimer's Association Announce the Winner of the C.A.R.E. Pharmacy Award 3PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma 2
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
(Date:4/21/2015)... -- High crime rate, increasing government ... control systems market in Saudi Arabia ... report by TechSci Research " Saudi Arabia Access Control Systems Market ... market in Saudi Arabia is ... systems market in the Kingdom is growing at a ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... In a new study published in the August 16th ... Medical Center identified a molecular mechanism that guarantees that new ... proper abundance. "We have known for a long time ... and that in some places of our bodies this branching ...
... CORVALLIS, Ore. A recent study suggests that parasites ... have more profound impacts on fish health than has been ... which habitat and land use changes cause salmon mortality. ... is important, the research found, but their numbers that can ...
... TORONTO, August 15, 2011 A study out of ... be good for you. Published today in the journal ... that obese people who are otherwise healthy live just as ... die of cardiovascular causes. "Our findings challenge the ...
Cached Biology News:Parasite loads an underlying cause of salmon mortality, linked to land use changes 2Fat and healthy? York U study finds slim isn't always superior 2
... Edited by R. Edwards (1996) ... all types of immunoassays, including ... immunoassays and on the photoluminescent ... Essential information is also given ...
EoProbe Eosinophil Staining Kit, 1 Kit...
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: